Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor

Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane, an adrenolytic and cytotoxic drug. In additi...

Full description

Bibliographic Details
Main Authors:	Philip D Oddie, Benjamin B Albert, Paul L Hofman, Craig Jefferies, Stephen Laughton, Philippa J Carter
Format:	Article
Language:	English
Published:	Bioscientifica 2018-08-01
Series:	Endocrinology, Diabetes & Metabolism Case Reports
Online Access:	https://edm.bioscientifica.com/view/journals/edm/2018/1/EDM18-0059.xml

Similar Items

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
by: Nadia Gagnon, et al.
Published: (2023-01-01)

Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01)

Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma
by: Sandra Martens, et al.
Published: (2023-12-01)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
by: Soraya Puglisi, et al.
Published: (2020-03-01)

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma
by: Magdalena Lech, et al.
Published: (2024-02-01)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
by: Sarah Allegra, et al.
Published: (2021-03-01)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
by: Walid Alam, et al.
Published: (2021-04-01)

Generation and characterization of a mitotane-resistant adrenocortical cell line
by: Eric Seidel, et al.
Published: (2020-02-01)

Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy
by: Letizia Canu, et al.
Published: (2024-01-01)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
by: Marilda Mormando, et al.
Published: (2023-08-01)

Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients’ Management
by: Aurora Schiavon, et al.
Published: (2023-11-01)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
by: Marco Lo Iacono, et al.
Published: (2021-10-01)

Endocrine Disruptors
by: Ayşegül AKSAN, et al.
Published: (2016-08-01)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
by: Sarah Allegra, et al.
Published: (2022-08-01)

Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line
by: Camila Bach, et al.
Published: (2022-11-01)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
by: Vittoria Basile, et al.
Published: (2020-09-01)

Endocrine disruptors also function as nervous disruptors and can be renamed endocrine and nervous disruptors (ENDs)
by: Gilles-Eric Seralini, et al.
Published: (2021-01-01)

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
by: Marta Bianchini, et al.
Published: (2021-10-01)

Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
by: Alexandraki, K, et al.
Published: (2010)

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
by: Maria Riedmeier, et al.
Published: (2024-06-01)

Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study
by: Lidia Cerquetti, et al.
Published: (2019-11-01)

Food packaging and endocrine disruptors
by: Leila Cristina Pedroso de Paula, et al.
Published: (2024-03-01)

Endocrine Disruptors and Prostate Cancer
by: Margherita Corti, et al.
Published: (2022-01-01)

Endocrine Disruptors and Breast Cancer
by: Cathrin Brisken
Published: (2008-05-01)

Health surveillance and endocrine disruptors
by: William Waissmann

Endocrine disruptors and congenital anomalies
by: Rittler Mônica, et al.
Published: (2002-01-01)

Endocrine disruptors and congenital anomalies
by: Mônica Rittler, et al.

Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma
by: You Joung Heo, et al.
Published: (2022-09-01)

CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
by: Cristina L Ronchi, et al.
Published: (2014-01-01)

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
by: Judit Tőke, et al.
Published: (2022-09-01)

The EDCMET Project: Metabolic Effects of Endocrine Disruptors
by: Jenni Küblbeck, et al.
Published: (2020-04-01)

Effect of endocrine disruptors on bacterial virulence
by: Audrey Thiroux, et al.
Published: (2023-11-01)

Endocrine Disruptor Chemicals and Children’s Health
by: Giada Di Pietro, et al.
Published: (2023-01-01)

Endocrine disruptors: emerging health concerns
by: Shahjada Selim
Published: (2023-09-01)

The impact of the endocrine disruptors on child health
by: Donjeta Bali, et al.
Published: (2023-09-01)

Endocrine disruptors: A rising menace
by: Bhanu Malhotra, et al.
Published: (2022-01-01)

Oestrogenic Endocrine Disruptors in the Placenta and the Fetus
by: Zi-Run Tang, et al.
Published: (2020-02-01)